Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.91B

Market cap82.91B

Price-Earnings ratio

18.62

Price-Earnings ratio18.62

Dividend yield

0.46%

Dividend yield0.46%

Average volume

738.85K

Average volume738.85K

High today

$791.08

High today$791.08

Low today

$765.07

Low today$765.07

Open price

$774.04

Open price$774.04

Volume

750.83K

Volume750.83K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $784.51, giving the company a market capitalization of 82.91B. It carries a P/E multiple of 18.62 and pays a dividend yield of 45.6%.

During the trading session on 2026-02-25, Regeneron(REGN) shares reached a daily high of $791.08 and a low of $765.07. At a current price of $784.51, the stock is +2.5% higher than the low and still -0.8% under the high.

Trading volume for Regeneron(REGN) stock has reached 750.83K, versus its average volume of 738.85K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Nasdaq 20h

FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis

(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with aller...

Simply Wall St 1d

Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals and Sanofi recently received U.S. FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS) in adults and children aged...

Benzinga 1d

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining? AFRS is a condition characterized by allergic hypersensitivity to fungi,...

Analyst ratings

72%

of 29 ratings

Buy

72.4%

Hold

27.6%

Sell

More REGN News

TipRanks 1d

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult and pedi...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

Constellation Brands

abrdn Physical Precious M…

ServiceNow

Cipher Mining

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.